Takeda Pharmaceutical said on March 2 that it has agreed to divest select non-core assets being marketed in Latin America to Brazil’s largest drug maker Hypera Pharma for US$825 million - the latest in a string of divestment deals aimed…
To read the full story
Related Article
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
BUSINESS
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





